This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

86.5 Mn North America and Europe Artificial Pancreas Systems Market Poised to Witness Steady Growth

Author: Ankush Nikam
by Ankush Nikam
Posted: Apr 13, 2017

Diabetes Type 1 segment is likely to prevail over Diabetes Type 2 segment in the North America and Europe artificial pancreas systems market

The Diabetes Type 1 segment was estimated to account for a little more than 95% market share in terms of value in the North America and Europe artificial pancreas systems market by 2016 end and is expected to experience an increase of more than 200 BPS in its market share by 2026 over 2016. The Diabetes Type 1 segment is expected to register high Y-o-Y growth rates throughout the forecast period. Revenue contribution of this segment is projected to increase at a CAGR of 12.9% over the forecast period to reach more than US$ 250 Mn by 2026. On the other hand the Diabetes Type 2 segment is expected to register low Y-o-Y growth rates throughout the forecast period. Revenue contribution of this segment to the North America and Europe artificial pancreas systems market is expected to increase at a CAGR of 4.1% over the forecast period. The Diabetes Type 1 segment dominated the North America and Europe artificial pancreas systems market in revenue terms in 2015, and the trend is projected to continue throughout the forecast period. The Diabetes Type 2 segment is expected to remain the least attractive segment in the North America and Europe artificial pancreas systems market in revenue terms with a low market attractiveness index of 0.02 over the forecast period.

Alarming rise in population and economic burden of diabetes worldwide is anticipated to impact the artificial pancreas systems market in North America and Europe

Diabetes is one of the chronic and life-threatening diseases that affects a large part of the global population. Diabetes, also known as diabetes mellitus, is a metabolic disorder wherein the pancreas are either not able to produce insulin or the body is not able to utilise the existing insulin to metabolise glucose. Insulin is an essential secretion (hormone) of the body that metabolises glucose received by the body during and after a meal. An increasing burden of managing and controlling diabetes is the most important factor prompting demand for artificial pancreas systems among the global diabetic population.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-na-3058

Conventional systems used for diabetes management have many drawbacks including the need to take insulin injections at multiple times and recalibrating the CGM devices, thereby making management of diabetes quite tedious. However, artificial pancreas systems are designed to be more portable and user friendly. Artificial pancreas systems are technologically advanced. On the other hand, the conventional insulin pumps or CGM devices are large in size and thus, people have social and psychological stigma regarding conventional insulin devices, which motivates them to opt for artificial pancreas systems. This particular factor is creating a robust development in the North America and Europe artificial pancreas systems market.

Artificial pancreas systems are envisioned to deliver a complete system known as a closed loop system that mimics a pancreatic activity of maintaining blood glucose levels by coalescing several technologies including a glucose monitoring device, a glucose sensor with cutting-edge algorithm software and an insulin pump. Manufacturers are competing to provide such high-end artificial pancreas systems to attract diabetic patients who intend to improve diabetes management.

Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-na-3058

Diabetes Type 1 segment is projected to dominate the North America and Europe artificial pancreas systems market throughout the period of assessment

Diabetes Type 1 disease indication segment dominated the North America artificial pancreas systems market in revenue terms in 2015 and is projected to continue to do so throughout the forecast period, recording a market attractiveness index of 2.0. In Western and Eastern Europe this segment is expected to remain the dominant disease indication segment throughout the projected period.

Browse Full Report@ http://www.futuremarketinsights.com/reports/north-america-and-europe-artificial-pancreas-systems-market

About Us – Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

CONTACT:

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

Email: sales@futuremarketinsights.compress@futuremarketinsights.com

Website: www.futuremarketinsights.com

Blog: http://fmiblog.com/

About the Author

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. Fmi is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India

Leave a Comment
Author Thumbnail
Please or Join to add a comment.
Author: Ankush Nikam

Ankush Nikam

Flag of United States
United States

Member since: Mar 17, 2017
Total live articles: 1309

Related Articles